CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$12.75 (−71.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Cytosorbents Corp grew revenue 3.1% to $37.22M over the twelve months to Jun 30, 2026. Free cash flow was -$9.30M.
Revenue
$37.22M
+3.1% vs. a year earlier
Operating income
-$12.93M
TTM Q2 2026
Free cash flow
-$9.30M
TTM Q2 2026
EPS, diluted
-$0.29
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $311.52M
- P/E ratio
- –
- Price to sales
- 8.37
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -2.98%
Fundamentals
- Revenue
- $37.22M
- Net income
- -$18.21M
- EPS, diluted
- -$0.29
- Free cash flow
- -$9.30M
- Book value per share
- -$0.01
- Diluted shares
- 63M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$37.22M+3.1% YoY
Gross profit
$26.65M+8.6% YoY
Operating income
-$12.93M
Net income
-$18.21M
EPS, diluted
-$0.29
Free cash flow
-$9.30M
Reported periodTrailing twelve months